Inflammatory bowel diseases (IBD), mainly comprising ulcerative colitis (UC) and Crohn's Disease, are most often a polygenic disorder with contributions from the intestinal microbiome, defects in barrier function, and dysregulated host responses to microbial stimulation. Strategies that target the microbiota have emerged as potential therapies and, of these, probiotics have gained the greatest attention. Herein, we isolated a strain of Lactobacillus paracasei R3 (L.p R3) with strong biofilm formation ability from infant feces. Interestingly, we also found L.p R3 strain can ameliorate the general symptoms of murine colitis, alleviate inflammatory cell infiltration and inhibit Th17 while promote Treg function in murine dextran sulfate sodium (DSS)-induced colitis. Overall, this study suggested that L.p R3 strain significantly improves the symptoms and the pathological damage of mice with colitis and influences the immune function by regulating Th17/Treg cell balance in DSS-induced colitis in mice.

中文翻译：

---

副干酪乳杆菌 R3 通过调节 Th17/Treg 细胞平衡保护小鼠免受葡聚糖硫酸钠 (DSS) 诱导的结肠炎

炎症性肠病 (IBD) 主要包括溃疡性结肠炎 (UC) 和克罗恩病，通常是一种多基因疾病，其原因是肠道微生物组、屏障功能缺陷和宿主对微生物刺激的反应失调。针对微生物群的策略已经成为潜在的治疗方法，其中益生菌获得了最大的关注。在此，我们从婴儿粪便中分离出一株具有强生物膜形成能力的副干酪乳杆菌R3（Lp R3）菌株。有趣的是，我们还发现 Lp R3 菌株可以改善小鼠结肠炎的一般症状，减轻炎症细胞浸润并抑制 Th17，同时促进小鼠葡聚糖硫酸钠（DSS）诱导的结肠炎中的 Treg 功能。总的来说，这项研究表明 L.